#Switzerland #ADCs #Ymmunobio #YB-800 #Riehen

Ymmunobio AG Achieves Significant Milestone with YB-800 ADCs

Ymmunobio AG, a leading biotech firm headquartered in Switzerland, has recently announced a groundbreaking achievement in the field of oncology. Their two-antibody drug conjugates (ADCs), known as YB-800ADC1 and YB-800ADC2, have completed preclinical proof of concept studies, reaching a pivotal milestone in cancer therapeutics development. This advancement has been supported by compelling results from both in vivo and in vitro testing, which demonstrated the remarkable anti-tumor efficacy of the ADCs.

Behind the Breakthrough

Derived from Ymmunobio's lead antibody YB-800, these ADCs target a novel and pioneering tumor marker, a significant development in cancer treatment. Utilizing established payloads alongside an innovative third-generation linker, these ADCs have exhibited impressive tumor growth inhibition rates of approximately 90%. This extraordinary outcome not only validates the scientific approach but also showcases the potential for addressing the urgent needs of cancer patients expressing this new tumor marker.

Peter Schiemann, CEO of Ymmunobio, emphasized the importance of these findings, stating, "These excellent results allow YB to move forward swiftly to prepare for the pivotal toxicology studies. This is a major step towards the clinical development of our ADCs in solid tumors and demonstrates the potential for YB's ADCs to address unmet needs for cancer patients expressing the new novel tumor marker."

Next Steps in Development

With the successful completion of these proof of concept studies, Ymmunobio is now poised to progress rapidly into critical toxicology studies, key for advancing towards clinical trials. The company’s commitment to developing innovative cancer therapies is evident in their strategic focus on the clinical development of ADCs specifically for solid tumors, an area with significant unmet medical needs.

Moreover, the data obtained from these studies not only reinforce the development of YB-800ADC1 and YB-800ADC2 but also support two radiopharmaceuticals based on YB-800, being developed in collaboration with the esteemed Paul Scherer Institute. This collaboration signifies the dedication to advancing comprehensive treatment options for solid tumors by integrating both targeted therapy and radiopharmaceutical approaches.

Ymmunobio’s Commitment to Oncology

Founded on a commitment to pioneering oncology research, Ymmunobio AG is at the forefront of developing innovative solutions to combat cancer. The company's research is primarily focused on a unique target receptor, aiming to offer effective treatment alternatives for solid tumors that currently lack adequate therapies. Currently in preclinical development, Ymmunobio is channeling efforts toward three key treatment modalities:
1. YB-800ADCs,
2. YB-800R, which is a radiopharmaceutical developed in collaboration with the Paul-Scherrer-Institute, and
3. YB-800BiTEs that feature aCD3.

The innovations from Ymmunobio represent a hopeful future for patients grappling with cancer, particularly those suffering from solid tumors that express the novel tumor marker targeted by the YB-800 ADCs.

For those interested in learning more about Ymmunobio's promising initiatives and advancements, inquiries can be directed to CEO Peter Schiemann at [email protected] or via the communications team at [email protected], +41 (0) 76 378 59 30.

As the clinical landscape continues to evolve, the promising results from Ymmunobio AG provide hope and excitement within the biotechnology community, marking a significant step towards creating effective cancer therapies.